醋酸倍他米松(Betamethasone Acetate) - 药物靶点：GR_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Betamethasone acetate (JAN/USP)

靶点

GR

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

皮肤和肌肉骨骼疾病其他疾病

在研适应症-

非在研适应症

白癜风

原研机构

江苏灵豹药业股份有限公司

在研机构-

非在研机构

江苏灵豹药业股份有限公司

权益机构-

最高研发阶段撤市

首次获批日期

中国 (1985-01-01),

白癜风

最高研发阶段(中国)撤市

特殊审评-

登录后查看时间轴

结构/序列

分子式C24H31FO6

InChIKeyAKUJBENLRBOFTD-QZIXMDIESA-N

CAS号987-24-6

关联

2

项与醋酸倍他米松相关的临床试验

IRCT2017103037105N1

/ Completed临床2/3期IIT

Study the effect of pre-operative doses of betamethasone acetate 0.1% on dry eye control and visual acuity after cataract surgery in patients referring to Khatam-al-Anbia hospital in 2016-2017

开始日期2016-11-04

申办/合作机构-

EUCTR2013-000873-56-ES

/ Recruiting临床4期IIT

Randomized, two paralel groups, open clinical trial stratified by severity to stimate the cost-effectivity of surgical vs corticosteroid injection treatment on carpal tunnel syndrome

开始日期2013-07-04

申办/合作机构-

100 项与醋酸倍他米松相关的临床结果

登录后查看更多信息

100 项与醋酸倍他米松相关的转化医学

登录后查看更多信息

100 项与醋酸倍他米松相关的专利（医药）

登录后查看更多信息

221

项与醋酸倍他米松相关的文献（医药）

2026-05-01·JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

Pharmacokinetics and Anti‐Inflammatory Effects of Intramuscular Betamethasone in Exercised Thoroughbred Horses

Article

作者: Daniel S. McKemie ; Juliana Sullivan ; Heather K. Knych ; Philip H. Kass ; Jeff Blea

ABSTRACT:

The pharmacokinetics and pharmacodynamics of betamethasone following intra‐articular administration to horses have been described; however, studies characterizing intramuscular administration are lacking. Twenty‐four horses received an intramuscular dose of 12 mg betamethasone sodium phosphate/betamethasone acetate. Blood and urine were collected at post administration for up to 408 h. Concentrations of betamethasone were determined using LC–MS/MS and pharmacokinetic parameters determined using a Population PK three‐compartment model. The duration of pharmacodynamic effects was assessed by measuring changes in cortisol and inflammatory biomarkers utilizing an ex vivo model. The Cmax , Tmax , and terminal half‐life of betamethasone were 6.43 ± 1.70 ng/mL, 0.75 (0.5–2.0 h; median and range), and 30.5 ± 20.4 h, respectively. Covariates were not found to have significant effects on the variability of pharmacokinetic parameters. Based on Monte Carlo simulations, for 1000 horses, a detection time of 23 days is recommended for concentrations to fall below the screening limit of 10 pg/mL in 99% of the population. Urine concentrations were above the limit of quantitation in 2/24 horses at 408 h. Suppression of cortisol lasted for 360 h. Effects on inflammatory biomarker production lasted for a prolonged period. An extended withdrawal time for intramuscular administration prior to competition is warranted.

2025-04-01·PHYTOMEDICINE

Exploring the anti-inflammatory effects of Radix Curcumae essential oil in pulmonary sarcoidosis via the TLR4/MyD88/NF-κB pathway

Article

作者: Zhou, Tianbao ; Liu, Ying ; Zhang, Jinying ; Mao, Zhiguo ; Lin, Xiangke ; Yu, Shuaike ; Tian, Shuo ; Miao, Mingsan ; Yang, Xingyi ; Hu, Yilong

BACKGROUND:

Pulmonary sarcoidosis (PS) is an immune-mediated disorder characterised by a significant association with various immune cell types including macrophages, T-helper 1 (TH1) cells, and TH17 cells. Dysregulation of immune cell differentiation leads to pronounced inflammatory responses in the pulmonary system, resulting in granuloma formation. Currently, the therapeutic approach for PS predominantly involves the use of immunosuppressive agents. However, the considerable adverse effects associated with these treatments underscore the urgent need to develop novel anti-PS pharmacological interventions.

PURPOSE:

To investigate whether essential oil from Radix Curcumae (RCEO) improves pulmonary function in PS mice by inhibiting inflammation mediated by the Toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear factor kappa-B (NF-κB) (TLR4/MyD88/NF-κB) pathway.

METHODS:

Bioinformatics and network pharmacology methodologies were used to predict potential therapeutic targets of RCEO in the context of PS. The primary components of RCEO were analysed using gas chromatography-mass spectrometry. A murine model of PS was established by induction with Propionibacterium acnes, and alterations in pulmonary function were evaluated using whole-body plethysmography. An enzyme-linked immunosorbent assay was used to measure changes in inflammatory mediators in the blood and bronchoalveolar lavage fluid. Additionally, flow cytometry was performed to determine the differentiation of CD4+ T cells into TH1 and TH17 subsets in the lung tissues of mice in the model group. Immunofluorescence analysis was used to quantify the differentiation of macrophages into M1 and M2 phenotypes in the lung tissues. Polymerase chain reaction (PCR) and western blotting (WB) were used to assess alterations in the mRNAs expression levels and proteins associated with the TLR4/MyD88/NF-κB signalling pathway in pulmonary tissues.

RESULTS:

Bioinformatics and network pharmacology predictions suggested that the therapeutic effects of RCEO on PS are linked to the modulation of inflammation via the TLR4/MyD88/NF-κB pathway. In a murine model of PS, RCEO significantly reduced pathological alterations in lung tissue and enhanced pulmonary function. Subsequent experimental analyses revealed that RCEO inhibited the differentiation of macrophages into M1-type macrophages and reduced the differentiation of CD4+ T cells into TH1 and TH17 cells, thereby preventing granuloma formation in the mouse pulmonary tissue. Further PCR and WB analyses indicated that RCEO modulated immune cell differentiation by inhibiting inflammation mediated through the TLR4/MyD88/NF-κB signalling pathway. Immunofluorescence experiments demonstrated that RCEO conferred a protective effect against PS by attenuating inflammation in macrophages.

CONCLUSION:

RCEO inhibited the differentiation of macrophages into M1-type macrophages and suppressed the differentiation of CD4+T cells into TH1 and TH17 cells by blocking the inflammatory response mediated by the TLR4/MyD88/NF-κB pathway. This further reduced the formation of granulomas in lung tissue and improved lung function in PS mice.

2025-04-01·Journal of Environmental Chemical Engineering

Development of scalable cultivation strategy for microalgal biomass generation using wastewater and integrated biorefinery approach for biofuel production

作者: Jagadale, Krushna ; Tilva, Jeel ; Singh, Bhaskar ; Gawali, Sushant ; Guldhe, Abhishek ; Alam, Shahrukh Nawaj

Microalgal biomass production using wastewater (WW) is a sustainable approach for economically viable biorefinery.The present study aims to develop a scalable cultivation strategy using novel microalgae strain Marvania coccoides for biofuels productionThe cultivation strategy based on nutrient supplementation is developed at lab-scale (1 L) and validated at open-raceway pond system (200 L).Nutrient-supplemented wastewater (OWW) showed higher biomass productivity at both lab-scale (87.36 mg.L-1.d-1) and open pond system (133.89 mg.L-1.d-1) as compared to synthetic media.Biodiesel yield of 92.30 % was achieved upon transesterification of lipids from OWW (200 L) medium.Moreover, the residual biomass, i.e., lipid-extracted microalgal (LEM) biomass, yielded in 26.65 % of bio-oil and 56.94 % of biochar upon non-catalytic pyrolysis.Bio-oil and biochar produced were analyzed using element analyzer, gas chromatog.-mass spectrometry (GC-MS), and fourier-transform IR spectroscopy (FTIR).This scalable cultivation strategy for microalgae and biorefinery approach for production of biodiesel, bio-oil and biochar is sustainable solution for managing wastes and generation of biofuels.

100 项与醋酸倍他米松相关的药物交易

登录后查看更多信息